Market Research Reports and Industry Reports

Retinal Vein Occlusion - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Retinal Vein Occlusion - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2017, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 3, 9, 2 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Retinal Vein Occlusion - Overview 8
Retinal Vein Occlusion - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Products under Development by Companies 12
Retinal Vein Occlusion - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type0
Retinal Vein Occlusion - Companies Involved in Therapeutics Development2
Acucela Inc2
Addmedica SAS2
Aerpio Therapeutics Inc2
Annexin Pharmaceuticals AB3
Chengdu Kanghong Pharmaceuticals Group Co Ltd3
Clearside BioMedical Inc3
Formycon AG4
Graybug Vision Inc4
Kala Pharmaceuticals Inc5
Lupin Ltd5
Mabion SA6
Novartis AG6
Ocular Therapeutix Inc7
Ohr Pharmaceutical Inc7
Regeneron Pharmaceuticals Inc8
SciFluor Life Sciences LLC8
ThromboGenics NV9
Retinal Vein Occlusion - Drug Profiles 30
ACU-6151 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
aflibercept biosimilar - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
aflibercept biosimilar - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
aflibercept SR - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AKB-9778 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
AP-01 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
conbercept - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
HO-10 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
hydroxyurea - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
KPI-285 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
LKA-651 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ocriplasmin - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
OTX-TKI - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Protein to Inhibit VEGF for Ophthalmology - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ranibizumab biosimilar - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ranibizumab biosimilar - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
ranibizumab biosimilar - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
SF-0166 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
squalamine lactate - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
sunitinib malate CR - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
triamcinolone acetonide - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Retinal Vein Occlusion - Dormant Projects 79
Retinal Vein Occlusion - Discontinued Products 80
Retinal Vein Occlusion - Product Development Milestones 81
Featured News & Press Releases 81
Jun 08,017: Clearside Biomedicals TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting 81
Feb 16,017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion 82
Oct 10,016: Clearside Biomedical to Report Clinical Trial Results at016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 82
Jul6,016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 83
Apr6,016: Clearside Biomedical Announces Positive Preliminary Phase Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 83
Dec 14,015: Clearside Biomedical Completes Enrollment in Phase Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 84
Jul 13,015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 85
Apr3,015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 86
Aug 11,014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 86
Aug0,013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 87
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List Of Tables

List of Tables
Number of Products under Development for Retinal Vein Occlusion, H2 2017 9
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products by Stage and Target, H2 2017 15
Number of Products by Stage and Mechanism of Action, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21
Retinal Vein Occlusion - Pipeline by Acucela Inc, H2 2017 22
Retinal Vein Occlusion - Pipeline by Addmedica SAS, H2 2017 22
Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics Inc, H2 2017 22
Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H2 2017 23
Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 23
Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H2 2017 24
Retinal Vein Occlusion - Pipeline by Formycon AG, H2 2017 24
Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H2 2017 25
Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals Inc, H2 2017 25
Retinal Vein Occlusion - Pipeline by Lupin Ltd, H2 2017 26
Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2017 26
Retinal Vein Occlusion - Pipeline by Novartis AG, H2 2017 27
Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H2 2017 27
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H2 2017 28
Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 28
Retinal Vein Occlusion - Pipeline by SciFluor Life Sciences LLC, H2 2017 29
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2017 29
Retinal Vein Occlusion - Dormant Projects, H2 2017 79
Retinal Vein Occlusion - Discontinued Products, H2 2017 80

Global Retinal Detachment Hook Market Professional Survey Report 2017

This report studies Retinal Detachment Hook in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions,

USD 3500View Report

Retinal Vein Occlusion - Pipeline Review, H2 2017

Retinal Vein Occlusion - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2017, provides an overview of the

USD 2000View Report

Retinal Vein Occlusion - Pipeline Insight, 2017

DelveInsights, Retinal Vein Occlusion-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Retinal Vein Occlusion. The report provides a complete understanding of the pipeline

USD 1250View Report

Branch Retinal Vein Occlusion Global Clinical Trials Review, H1, 2017

Branch Retinal Vein Occlusion Global Clinical Trials Review, H1, 2017GlobalDatas clinical trial report, Branch Retinal Vein Occlusion Global Clinical Trials Review, H1, 2017 provides an overview of Branch Retinal Vein

USD 2500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :90
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube